Ameet Sarpatwari1, Joshua J Gagne2, Zhigang Lu2, Eric G Campbell3, Wendy J Carman4, Cheryl L Enger4, Sarah K Dutcher5, Wenlei Jiang5, Aaron S Kesselheim2. 1. Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. asarpatwari@bwh.harvard.edu. 2. Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 3. Center for Bioethics and Humanities, University of Colorado, Denver, CO, USA. 4. Epidemiology, Optum, Ann Arbor, MI, USA. 5. Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Abstract
BACKGROUND: Generic versions of a drug can vary in appearance, which can impact adherence. OBJECTIVE: To assess the preferences, perceptions, and responses of patients who experienced a change in the appearance of a generic medication. DESIGN: Cross-sectional survey of patients from a large commercial health plan. PARTICIPANTS: Adults receiving generic versions of lisinopril, fluoxetine, lamotrigine, or simvastatin who experienced a change in the color or shape of their pills between March 2014 and November 2015. MAIN MEASURES: Likert-scale responses to questions concerning perceptions of generic drug safety and effectiveness, reliance on and preferences for pill appearance, and responses to pill appearance changes. Multivariable logistic regression-modeled predictors of seeking advice and adjusting use following a pill appearance change. KEY RESULTS: Of 814 respondents (response rate = 41%), 72% relied on pill appearance to ensure they took the correct medication. A similar percentage wanted their pills to remain the same color (72%), shape (71%), and size (75%) upon refill, but 58% would not have paid a $1 premium on a $5 co-pay to ensure such consistency. Most respondents (86%) wanted their pharmacists to notify them about pill appearance changes, but only 37% recalled such notification; 21% thought they received the wrong medication, and 8% adjusted medication use. Younger respondents (18-33 vs. 50-57 years) were more likely to seek advice (odds ratio [OR] = 1.91; 95% confidence interval [CI],1.02-3.59), and respondents with lower household income (< $30,000 vs. > $100,000) were more likely to adjust medication use (OR = 3.40; 95% CI,1.09-10.67). CONCLUSIONS: Requiring uniform pill appearance may help increase adherence but presents challenges. Standardized pharmacy notification and education policies may be a more feasible short-term solution.
BACKGROUND: Generic versions of a drug can vary in appearance, which can impact adherence. OBJECTIVE: To assess the preferences, perceptions, and responses of patients who experienced a change in the appearance of a generic medication. DESIGN: Cross-sectional survey of patients from a large commercial health plan. PARTICIPANTS: Adults receiving generic versions of lisinopril, fluoxetine, lamotrigine, or simvastatin who experienced a change in the color or shape of their pills between March 2014 and November 2015. MAIN MEASURES: Likert-scale responses to questions concerning perceptions of generic drug safety and effectiveness, reliance on and preferences for pill appearance, and responses to pill appearance changes. Multivariable logistic regression-modeled predictors of seeking advice and adjusting use following a pill appearance change. KEY RESULTS: Of 814 respondents (response rate = 41%), 72% relied on pill appearance to ensure they took the correct medication. A similar percentage wanted their pills to remain the same color (72%), shape (71%), and size (75%) upon refill, but 58% would not have paid a $1 premium on a $5 co-pay to ensure such consistency. Most respondents (86%) wanted their pharmacists to notify them about pill appearance changes, but only 37% recalled such notification; 21% thought they received the wrong medication, and 8% adjusted medication use. Younger respondents (18-33 vs. 50-57 years) were more likely to seek advice (odds ratio [OR] = 1.91; 95% confidence interval [CI],1.02-3.59), and respondents with lower household income (< $30,000 vs. > $100,000) were more likely to adjust medication use (OR = 3.40; 95% CI,1.09-10.67). CONCLUSIONS: Requiring uniform pill appearance may help increase adherence but presents challenges. Standardized pharmacy notification and education policies may be a more feasible short-term solution.
Authors: Maja Hellfritzsch; Jette Rathe; Tore Bjerregaard Stage; Steffen Thirstrup; Erik L Grove; Per Damkier; Anton Pottegård Journal: Pharmacoepidemiol Drug Saf Date: 2015-12-22 Impact factor: 2.890
Authors: Aaron S Kesselheim; Alexander S Misono; William H Shrank; Jeremy A Greene; Michael Doherty; Jerry Avorn; Niteesh K Choudhry Journal: JAMA Intern Med Date: 2013-02-11 Impact factor: 21.873
Authors: Aaron S Kesselheim; Joshua J Gagne; Wesley Eddings; Jessica M Franklin; Kathryn M Ross; Lisa A Fulchino; Eric G Campbell Journal: JAMA Intern Med Date: 2016-06-01 Impact factor: 21.873
Authors: Michael D Privitera; Timothy E Welty; Barry E Gidal; Francisco J Diaz; Ron Krebill; Jerzy P Szaflarski; Barbara A Dworetzky; John R Pollard; Edmund J Elder; Wenlei Jiang; Xiaohui Jiang; Michel Berg Journal: Lancet Neurol Date: 2016-02-12 Impact factor: 44.182
Authors: Joshua J Gagne; Aaron S Kesselheim; Niteesh K Choudhry; Jennifer M Polinski; David Hutchins; Olga S Matlin; Troyen A Brennan; Jerry Avorn; William H Shrank Journal: Epilepsy Behav Date: 2015-09-19 Impact factor: 2.937
Authors: Aaron S Kesselheim; Alexander S Misono; Joy L Lee; Margaret R Stedman; M Alan Brookhart; Niteesh K Choudhry; William H Shrank Journal: JAMA Date: 2008-12-03 Impact factor: 56.272
Authors: Aaron S Kesselheim; Joshua J Gagne; Jessica M Franklin; Wesley Eddings; Lisa A Fulchino; Jerry Avorn; Eric G Campbell Journal: J Gen Intern Med Date: 2016-02-16 Impact factor: 5.128
Authors: William H Shrank; Tuyen Hoang; Susan L Ettner; Peter A Glassman; Kavita Nair; Dee DeLapp; June Dirstine; Jerry Avorn; Steven M Asch Journal: Arch Intern Med Date: 2006-02-13
Authors: Sharmila Das; Dong Guo; Xiaohui Jiang; Wenlei Jiang; Yan Shu; Tricia Y Ting; James E Polli Journal: Pharm Res Date: 2020-02-26 Impact factor: 4.200